For years, Big Pharma has had its eye on mRNA gene transfer technology. In 2019, a Milken Institute panel specifically discussed how they might achieve the transition from conventional vaccine development to novel mRNA technology.1 You can listen to key excerpts from that meeting in the video below.
Participants included Dr. Anthony Fauci, director of the National Institutes of Allergy and Infectious Diseases (NIAID), and Rick Bright, Ph.D., former director of the U.S. Biomedical Advanced Research and Development Authority (BARDA), now a senior vice president of Pandemic Prevention and Response at The Rockefeller Foundation.
Bright suggested “There may be a need, even an urgent call, for an entity of excitement out there which is completely disruptive, not beholden to bureaucratic strings and processes.”
